A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy

Conditions:   Lupus Erythematosus, Cutaneous, Subacute;   Chronic Cutaneous Lupus Erythematosus Intervention:   Drug: BIIB059 (litifilimab) Sponsor:   Biogen Not yet recruiting

Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials